CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma
- PMID: 12702507
- DOI: 10.1182/blood-2002-11-3333
CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma
Abstract
CD20 has been reinvestigated in 66 patients with multiple myeloma (MM). Twelve of the patients (18%) expressed CD20, including 5 of 50 patients at diagnosis presenting 100% CD20+ cells. Seven (58%) of 12 CD20+ patients with MM had a small mature plasma cell morphology as opposed to 4 (7%) of 54 with CD20- MM (P =.0001). Of note, 10 (83%) of 12 patients with CD20+ MM had t(11;14) as opposed to 5 of 54 (9%) CD20- patients (P <.001). All the patients with 100% CD20+ cells presented with t(11;14) and 4 of 5 with a small mature plasma cell morphology. Thus, 66% of the patients with t(11;14) expressed CD20, whereas only 4% of the 51 patients lacking such translocation expressed CD20 (P <.0001). In conclusion, CD20 expression is associated with small mature plasma cell morphology and with t(11;14) in patients with MM.
Similar articles
-
[Close correlations between CD20 expression, a small mature plasma cell morphology and t(11 ; 14) in multiple myeloma].Rinsho Ketsueki. 2005 Dec;46(12):1293-7. Rinsho Ketsueki. 2005. PMID: 16447802 Japanese.
-
Mott cells in CD20-positive myeloma.Br J Haematol. 2011 Feb;152(4):366. doi: 10.1111/j.1365-2141.2010.08508.x. Epub 2011 Jan 7. Br J Haematol. 2011. PMID: 21265822 No abstract available.
-
Neoplastic plasma cells mimic mature neutrophils in plasma cell myeloma with t(11;14)(q13;q32).Blood. 2015 Apr 30;125(18):2875. doi: 10.1182/blood-2014-12-617795. Blood. 2015. PMID: 26120642 No abstract available.
-
Many and multiple myeloma(s).Leukemia. 2003 Oct;17(10):1943-4. doi: 10.1038/sj.leu.2403090. Leukemia. 2003. PMID: 14513042 Review. No abstract available.
-
Anti-CD20 monoclonal antibody therapy in multiple myeloma.Br J Haematol. 2008 Apr;141(2):135-48. doi: 10.1111/j.1365-2141.2008.07024.x. Epub 2008 Mar 3. Br J Haematol. 2008. PMID: 18318769 Review.
Cited by
-
Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma.Eur J Haematol. 2017 Mar;98(3):263-268. doi: 10.1111/ejh.12826. Epub 2016 Dec 1. Eur J Haematol. 2017. PMID: 27862330 Free PMC article.
-
A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma.Bone Marrow Transplant. 2017 Oct;52(10):1372-1377. doi: 10.1038/bmt.2017.164. Epub 2017 Sep 4. Bone Marrow Transplant. 2017. PMID: 28869617 Clinical Trial.
-
Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.Biol Blood Marrow Transplant. 2013 Aug;19(8):1227-32. doi: 10.1016/j.bbmt.2013.05.017. Epub 2013 May 31. Biol Blood Marrow Transplant. 2013. PMID: 23733001 Free PMC article.
-
Association of Chromosomal Translocation and MiRNA Expression with The Pathogenesis of Multiple Myeloma.Cell J. 2014 Summer;16(2):99-110. Epub 2014 May 25. Cell J. 2014. PMID: 24567933 Free PMC article. Review.
-
Multiple myeloma with t(11;14): unique biology and evolving landscape.Am J Cancer Res. 2022 Jul 15;12(7):2950-2965. eCollection 2022. Am J Cancer Res. 2022. PMID: 35968339 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical